Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Remote Intervention to improVe Use of Evidence-based Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 27 - 79 years at the time of agreeing to participate in the program~2. Presence of type 2 diabetes (treated with metformin unless intolerant, may also be treated with DPP4i, sulfonylurea, pioglitazone, and/or basal insulin)~3. HbA1c 6.5-8.9%; AND~4. At elevated cardiovascular and/or renal risk defined as any diagnosed ASCVD, estimated ASCVD risk \>10%, congestive heart failure, non-alcoholic fatty liver disease, estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2, albuminuria above 300mg/g; and those aged 60 years or older with at least two of: active tobacco use, dyslipidemia (LDL-c above 160 mg/dL or 4.1 mmol/L, non-HDL-C above 190 mg/dL or 4.9 mmol/L, triglycerides above 175 mg/dL,) hypertension (2 systolic blood pressure values above 130 mmHg and/or 2 diastolic blood pressure values above 90 mmHg within 12 months,) or BMI above 30~5. Has seen a primary care provider within the Mass General Brigham network within the last year~Exclusion Criteria:~1. Type 1 diabetes~2. Currently or previously prescribed an SGLT2i or GLP1-RA~3. Taking any short-acting insulin~4. History of diabetic ketoacidosis~5. History of hypoglycemia requiring hospitalization~6. Frequent (more than two times in 1 week) episodes of symptomatic hypoglycemia with blood glucose \<70 mg/dL~7. eGFR below 15 ml/min/m2~8. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation, OR~9. Life expectancy less than 1 year or utilizing palliative care

- Gender: ALL
- Minimum Age: 27 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Medication & Education-First (Type: ACTIVE_COMPARATOR): Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
- Education-First (Type: EXPERIMENTAL): Patient will first receive curated patient education, an alert to providers, and provider education, and then after 2 months begin participation in the remote clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).